A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Trial details
- Registry ID
- NCT06760546
- Drugs studied
- Setmelanotide
TrialRedline tracks 18 clinical trials sponsored by Rhythm Pharmaceuticals, Inc.: 8 Phase 3, 1 Phase 2 / 3, 8 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Long Term Extension Trial of SetmelanotideNCT03651765 | Setmelanotide | Completed | 2025-01-09Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentNCT06239116 | Part C: RM-718, Part D: RM-718 | Active not recruiting | 2027-05-07Estimated |
Names as written in the registry records.
NCT06772597 · Rhythm Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 31 Oct 2026. After: 3 Nov 2026.
NCT05093634 · Rhythm Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI Time frame: Baseline to 52 weeks. After: Measure: Treatment Period: Percent Change From Baseline in Body Mass Index (BMI) Description: BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters \[m\])\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate. Time frame: Baseline, Week 52.
Before: 22 Dec 2025. After: 19 Dec 2025.
NCT06046443 · Rhythm Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean percentage change in BMI Time frame: From Baseline to Week 14. After: Measure: Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI) Description: BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate. Time frame: Baseline, Week 14.
NCT05093634 · Rhythm Pharmaceuticals, Inc.
Before: Active not recruiting. After: Completed.
NCT06596135 · Rhythm Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 30 participants (planned). After: 28 participants (actual).
Before: Estimated. After: Actual.
Before: 30 Oct 2027. After: 24 Jun 2026.
Before: Enrolling by invitation. After: Completed.
NCT05774756 · Rhythm Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean % change in BMI. After: Measure: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen.
Before: Estimated. After: Actual.
Before: 120 participants (planned). After: 143 participants (actual).
NCT06046443 · Rhythm Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: Estimated. After: Actual.
Before: 31 Jan 2026. After: 9 Feb 2026.
Before: Active not recruiting. After: Completed.
NCT06772597 · Rhythm Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 20 participants (planned). After: 18 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT06760546 · Rhythm Pharmaceuticals, Inc.
Before: 30 Sep 2026. After: 13 Mar 2027.
NCT05093634 · Rhythm Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 400 participants (planned). After: 296 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2025. After: 22 Dec 2025.